Webster Bank N. A. Has $11.34 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Webster Bank N. A. trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,510 shares of the medical research company’s stock after selling 1,258 shares during the period. Thermo Fisher Scientific accounts for about 1.3% of Webster Bank N. A.’s portfolio, making the stock its 17th biggest holding. Webster Bank N. A.’s holdings in Thermo Fisher Scientific were worth $11,339,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in TMO. KRS Capital Management LLC increased its stake in shares of Thermo Fisher Scientific by 6.2% during the first quarter. KRS Capital Management LLC now owns 1,430 shares of the medical research company’s stock worth $831,000 after purchasing an additional 83 shares during the period. New England Research & Management Inc. bought a new position in Thermo Fisher Scientific during the 1st quarter worth $349,000. Harbour Capital Advisors LLC increased its stake in Thermo Fisher Scientific by 0.9% during the 1st quarter. Harbour Capital Advisors LLC now owns 7,447 shares of the medical research company’s stock worth $4,256,000 after acquiring an additional 64 shares during the period. Fifth Third Wealth Advisors LLC increased its stake in Thermo Fisher Scientific by 24.3% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 2,397 shares of the medical research company’s stock worth $1,393,000 after acquiring an additional 469 shares during the period. Finally, Dohj LLC bought a new position in Thermo Fisher Scientific during the 1st quarter worth $600,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $70,238,340.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the transaction, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. In the last ninety days, insiders sold 22,000 shares of company stock valued at $12,532,780. Corporate insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on TMO. The Goldman Sachs Group raised their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Robert W. Baird decreased their price target on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research note on Thursday, April 25th. HSBC lifted their price target on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. Citigroup initiated coverage on Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target on the stock. Finally, Barclays decreased their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a research note on Friday. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $607.06.

Thermo Fisher Scientific Trading Up 0.4 %

TMO traded up $2.22 during midday trading on Friday, hitting $553.00. 6,150,885 shares of the company were exchanged, compared to its average volume of 1,473,906. The firm has a market capitalization of $211.09 billion, a P/E ratio of 35.45, a P/E/G ratio of 2.57 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The firm’s 50 day moving average price is $574.84 and its 200-day moving average price is $562.59. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping the consensus estimate of $4.70 by $0.41. The firm had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Friday, June 14th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. The ex-dividend date is Friday, June 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.